News ImmuneRegen NewsImmuneRegen BioSciences Appoints Pranela Rameshwar to Advisory BoardDecember 18, 2007 7:00 AM ET ImmuneRegen BioSciences, Inc., a wholly-owned subsidiary of IR BioSciences Holdings, Inc. IRBO today announced the appointment of Pranela Rameshwar, Ph.D., to its scientific advisory board. Dr. Rameshwar has been directing academic research programs for over 15 years and is an internationally-recognized thought leader in the field of regenerative medicine, genetics, and stem cell research. Hal Siegel, Ph.D., Vice President and Chief Scientific Officer of ImmuneRegen, said, "As we continue to develop drug candidates that will enhance the healing process of the human body, it is essential that we build a team of key opinion leaders who can add value to our scientific research. Dr. Rameshwar has spent her entire career writing, lecturing, and teaching on precisely the areas we are targeting, including bone marrow stem cells and control mechanisms impacting cellular growth control and wound healing. Her contacts in academia and industry and ability to refine our scientific discovery process will be invaluable as we work to commercialize our drug candidates." Dr. Rameshwar is a professor at The University of Medicine and Dentistry of New Jersey, where she is a faculty member in the Medicine Department, Division of Hematology/Oncology, where she teaches and conduct translational research. She received her undergraduate degree in Medical Microbiology from the University of Wisconsin, and her Ph.D. in Biology from Rutgers University. Dr. Rameshwar wrote her doctoral thesis on the stimulatory effect of substance P on the immune system, which adds value at ImmuneRegen because its developmental candidate Homspera(TM) is related to substance P. She has written over 100 articles on regenerative medicine, genetics, and stem cell research and has presented over 140 abstracts at national and international meetings including the American Society of Hematology, the American Society of Immunologists, and the American Association for Cancer Research. She holds nine U.S. patents. Her research interests include hematopoiesis, properties of mesenchymal stem cells and factors impacting their transdifferentiation to neurons, and identification of breast cancer stem cells in bone marrow. Michael Wilhelm, President and Chief Executive Officer of ImmuneRegen concluded, "Dr. Rameshwar's reputation as a skillful scientist and innovative researcher will help augment our internal efforts as we accelerate our relationship development activities in wound healing and stem cell proliferation, differentiation and targeting. We look forward to her contribution to our company." About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|